- $727.24m
- $741.26m
- $187.34m
- 86
- 15
- 80
- 63
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 46.74 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7 | ||
| Price to Tang. Book | 7.4 | ||
| Price to Free Cashflow | 66,112.55 | ||
| Price to Sales | 3.88 | ||
| EV to EBITDA | 162.91 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.9% | ||
| Return on Equity | -9.99% | ||
| Operating Margin | -1.75% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 112.3 | 127.36 | 138.58 | 159.01 | 187.34 | 216.9 | 252.24 | 11.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +79.64 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
Directors
- Karen Zaderej CHM (59)
- Peter Mariani CFO (57)
- Maria Martinez CHO (53)
- Brad Ottinger CCO (51)
- Mike Donovan VOP (56)
- Erick DeVinney VPR (45)
- Mark Friedman VPR (63)
- Isabelle Billet OTH (59)
- Eric Sandberg OTH (56)
- Angelo Scopelianos OTH (66)
- Amy Wendell LED (61)
- John Johnson DRC (63)
- Quentin Blackford IND (43)
- Gregory Freitag IND (59)
- Mark Gold IND (72)
- Alan Levine IND (53)
- Guido Neels IND (72)
- Paul Thomas IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 20th, 1977
- Public Since
- December 17th, 1986
- No. of Shareholders
- 218
- No. of Employees
- 451
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 44,343,785
- Address
- SUITE 100, 13859 PROGRESS BLVD., ALACHUA, 32615
- Web
- https://www.axogeninc.com/
- Phone
- +1 3864626817
- Auditors
- Deloitte & Touche LLP
Latest News for AXGN
Upcoming Events for AXGN
Q1 2025 AxoGen Inc Earnings Call
Q1 2025 AxoGen Inc Earnings Release
AxoGen Inc Annual Shareholders Meeting
Q2 2025 AxoGen Inc Earnings Release
Similar to AXGN
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
As of Today at 19:28 UTC, shares in AxoGen are trading at $16.40. This share price information is delayed by 15 minutes.
Shares in AxoGen last closed at $16.40 and the price had moved by +151.53% over the past 365 days. In terms of relative price strength the AxoGen share price has outperformed the S&P500 Index by +132.17% over the past year.
The overall consensus recommendation for AxoGen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAxoGen does not currently pay a dividend.
AxoGen does not currently pay a dividend.
AxoGen does not currently pay a dividend.
To buy shares in AxoGen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $16.40, shares in AxoGen had a market capitalisation of $727.24m.
Here are the trading details for AxoGen:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AXGN
Based on an overall assessment of its quality, value and momentum AxoGen is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in AxoGen is $26.13. That is 59.33% above the last closing price of $16.40.
Analysts covering AxoGen currently have a consensus Earnings Per Share (EPS) forecast of $0.28 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AxoGen. Over the past six months, its share price has outperformed the S&P500 Index by +29.87%.
As of the last closing price of $16.40, shares in AxoGen were trading +11.47% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AxoGen PE ratio based on its reported earnings over the past 12 months is 46.74. The shares last closed at $16.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
AxoGen's management team is headed by:
- Karen Zaderej - CHM
- Peter Mariani - CFO
- Maria Martinez - CHO
- Brad Ottinger - CCO
- Mike Donovan - VOP
- Erick DeVinney - VPR
- Mark Friedman - VPR
- Isabelle Billet - OTH
- Eric Sandberg - OTH
- Angelo Scopelianos - OTH
- Amy Wendell - LED
- John Johnson - DRC
- Quentin Blackford - IND
- Gregory Freitag - IND
- Mark Gold - IND
- Alan Levine - IND
- Guido Neels - IND
- Paul Thomas - IND